Expanded indication enables broader access to objective, biomarker-based autism assessment and measurement of outcomes over time Plymouth, MN, March 12, 2026 —
Most ABA practices have a website. Most have a Google Business Profile. And most are invisible to the families who need them.
A child who does not follow directions can look, from the outside, like a child who is choosing not to. The instruction
If your baby avoids eye contact, turns away when you look at them, seems to gaze past you, or doesn’t hold your
You ask your child a question. They don’t look at you. Their gaze drifts to the corner of the room, or the
Parents ask me about this all the time. Their child can have a long, detailed conversation with an adult about weather systems,
There is a moment many families recognize. A question is asked or a conversation begins, and then there is silence. Not the
I’ve been thinking a lot lately about a question that sparked an incredible—and at times, heated—debate on a LinkedIn post I recently
When a parent brings a child in for a developmental evaluation, the goal is not simply to answer “autism or not.” The
There is a moment many parents know well. A child becomes overwhelmed, and everything suddenly escalates. Screaming, crying, running, hitting, and collapsing
A diagnosis of autism spectrum disorder can feel like the world has shifted beneath your feet. For some parents, it brings relief.
Every parent who has watched another child talk in full sentences while their own toddler stays quiet has felt that particular anxiety.
Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.
Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.
Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.